Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H50O2 |
Molecular Weight | 454.7275 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(C)=O)[C@H](C)\C=C\[C@@H](CC)C(C)C
InChI
InChIKey=IZEUIYYDWBKERE-ZRODXFKISA-N
InChI=1S/C31H50O2/c1-8-23(20(2)3)10-9-21(4)27-13-14-28-26-12-11-24-19-25(33-22(5)32)15-17-30(24,6)29(26)16-18-31(27,28)7/h9-11,20-21,23,25-29H,8,12-19H2,1-7H3/b10-9+/t21-,23-,25+,26+,27-,28+,29+,30+,31-/m1/s1
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: O75469|||Q9UJ26 Gene ID: 8856.0 Gene Symbol: NR1I2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17622954 |
|||
Target ID: Q96RI1 Gene ID: 9971.0 Gene Symbol: NR1H4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17622954 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17622954
Cells, transfected with retinoic X receptor (RXR), hRXR alpha , were treated with agonist or agonist plus 10 uM stigmasterol acetate (StigAc) and 24 h later harvested and processed, and luciferase activities normalized as before. The agonist ligandsused were FXR, CDCA(100 uM); pregnane X receptor (PXR), peroxisome proliferator-activated receptor gamma (PPAR gamma), rosiglitazone(1 uM). Increasing concentrations of StigAc (0–10 uM) suppress CDCA-activated FXR with an IC50 of 5–10 uM, which is well below the physiologic range of Stig levels found in the serum of patients with serological evidence of PNAC. In addition to suppressing CDCA-activated FXR-LBD activity, StigAc also suppresses ligand-activated PXR-LBD activity. Except for a slight increase in RXR alpha LBD activity, StigAc has no discernible effect on any other NRLBD tested.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6437330
Created by
admin on Fri Dec 15 15:10:29 GMT 2023 , Edited by admin on Fri Dec 15 15:10:29 GMT 2023
|
PRIMARY | |||
|
225-082-7
Created by
admin on Fri Dec 15 15:10:29 GMT 2023 , Edited by admin on Fri Dec 15 15:10:29 GMT 2023
|
PRIMARY | |||
|
P5M1K7SCX9
Created by
admin on Fri Dec 15 15:10:29 GMT 2023 , Edited by admin on Fri Dec 15 15:10:29 GMT 2023
|
PRIMARY | |||
|
8109
Created by
admin on Fri Dec 15 15:10:29 GMT 2023 , Edited by admin on Fri Dec 15 15:10:29 GMT 2023
|
PRIMARY | |||
|
69434
Created by
admin on Fri Dec 15 15:10:29 GMT 2023 , Edited by admin on Fri Dec 15 15:10:29 GMT 2023
|
PRIMARY | |||
|
DTXSID301315192
Created by
admin on Fri Dec 15 15:10:29 GMT 2023 , Edited by admin on Fri Dec 15 15:10:29 GMT 2023
|
PRIMARY | |||
|
4651-48-3
Created by
admin on Fri Dec 15 15:10:29 GMT 2023 , Edited by admin on Fri Dec 15 15:10:29 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD